Dsuvia (sufentanil) sublingual tablet 30 mcg
visit dsuvia.com »
Please see DSUVIA Important Safety Information, including Boxed Warnings and Full Prescribing Information.
visit dsuvia.com »
Please see DSUVIA Important Safety Information, including Boxed Warnings and Full Prescribing Information.

About AcelRx

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.

Zalviso: In Phase III

Zalviso™Zalviso™

Approved in Europe, Zalviso delivers a 15 mcg sublingual dose of sufentanil via a novel preprogrammed device—providing an alternative to IV patient-controlled analgesia in the hospital. Zalviso is an investigational drug. It is not approved by the FDA. AcelRx makes no claims regarding the safety or effectiveness of Zalviso.

proprietary sublingual technology

DSUVIA® and Zalviso® were both developed using this proprietary sublingual technology.

Learn More